S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Costa Inc stock logo
ATX
Costa
$2,934.88
$0.00
$0.00
N/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
$0.00
$0.25
$6.30
$111.86MN/A2.15 million shs336,508 shs
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
$0.48
-14.2%
$0.00
$1.69
$14.81
$1.18MN/A102,599 shs213,231 shs
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$0.38
C$0.45
C$0.35
C$0.67
C$42.20M0.8261,343 shs6,215 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Costa Inc stock logo
ATX
Costa
0.00%0.00%0.00%0.00%0.00%
Biopharmx Corp stock logo
BPMX
Biopharmx
0.00%0.00%0.00%0.00%0.00%
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
0.00%-1.32%-10.71%-7.41%-44.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Costa Inc stock logo
ATX
Costa
N/AN/AN/AN/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Costa Inc stock logo
ATX
Costa
N/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Costa Inc stock logo
ATX
Costa
N/AN/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$25.87M1.63C$0.04 per share8.93C$0.25 per share1.50

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Costa Inc stock logo
ATX
Costa
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/A0.00N/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
-C$16.96M-C$0.17N/AN/A-65.57%-47.87%-15.68%4/25/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Costa Inc stock logo
ATX
Costa
N/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Costa Inc stock logo
ATX
Costa
N/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
71.36
1.52
1.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Costa Inc stock logo
ATX
Costa
N/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
0.03%

Insider Ownership

CompanyInsider Ownership
Costa Inc stock logo
ATX
Costa
N/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
7.11%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Costa Inc stock logo
ATX
Costa
N/AN/AN/ANot Optionable
Biopharmx Corp stock logo
BPMX
Biopharmx
1718.28 millionN/ANot Optionable
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
312.44 millionN/ANot Optionable
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
249112.54 millionN/ANot Optionable

BPMX, HEB, ATX, and NSCI Headlines

SourceHeadline
Nanalysis Announces Full Year 2023 Conference CallNanalysis Announces Full Year 2023 Conference Call
ca.finance.yahoo.com - April 11 at 10:39 AM
Nanalysis Scientific Corp. Announces Director ResignationNanalysis Scientific Corp. Announces Director Resignation
ca.finance.yahoo.com - April 10 at 10:29 AM
Nanalysis Scientific (CVE:NSCI) Shares Up 2.7%Nanalysis Scientific (CVE:NSCI) Shares Up 2.7%
americanbankingnews.com - April 9 at 2:16 AM
AI Revolutionizes Drug Detection with Compact NMR and Machine LearningAI Revolutionizes Drug Detection with Compact NMR and Machine Learning
theglobeandmail.com - April 4 at 4:36 PM
Scientists identify distinct molecular signatures for sepsis diagnosis and prognosisScientists identify distinct molecular signatures for sepsis diagnosis and prognosis
msn.com - March 31 at 8:59 PM
Insider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Acquires 80,000 Shares of StockInsider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Acquires 80,000 Shares of Stock
insidertrades.com - March 19 at 5:39 AM
Canadian Investment Regulatory Organization Trading Halt - NSCICanadian Investment Regulatory Organization Trading Halt - NSCI
ca.finance.yahoo.com - March 6 at 6:23 PM
Canadian Investment Regulatory Organization Trade Resumption - NSCICanadian Investment Regulatory Organization Trade Resumption - NSCI
finance.yahoo.com - March 6 at 6:23 PM
Nanalysis Scientific Corp.: Nanalysis Achieves Record Revenue in Q4Nanalysis Scientific Corp.: Nanalysis Achieves Record Revenue in Q4
finanznachrichten.de - February 6 at 1:27 PM
Nanalysis Scientific says Q4 revenue expected to be at least $9.3MNanalysis Scientific says Q4 revenue expected to be at least $9.3M
msn.com - February 6 at 1:27 PM
Nanalysis Achieves Record Revenue in Q4Nanalysis Achieves Record Revenue in Q4
finance.yahoo.com - February 6 at 9:43 AM
Nanalysis Scientific Corp. Provides Update on Security Services BusinessNanalysis Scientific Corp. Provides Update on Security Services Business
finance.yahoo.com - January 30 at 8:55 AM
Closing Bell: Nanalysis Scientific Corp flat on Thursday (NSCI)Closing Bell: Nanalysis Scientific Corp flat on Thursday (NSCI)
theglobeandmail.com - December 15 at 9:47 AM
Nanalysis Scientific Corp Ordinary Shares NSCINanalysis Scientific Corp Ordinary Shares NSCI
morningstar.com - December 2 at 2:33 PM
Nanalysis Scientific Corp.: Nanalysis Reports Third Quarter 2023 ResultsNanalysis Scientific Corp.: Nanalysis Reports Third Quarter 2023 Results
finanznachrichten.de - December 1 at 3:28 PM
Nanalysis Reports Third Quarter 2023 ResultsNanalysis Reports Third Quarter 2023 Results
finance.yahoo.com - November 29 at 7:47 PM
Nanalysis Announces Third Quarter 2023 Conference CallNanalysis Announces Third Quarter 2023 Conference Call
finance.yahoo.com - November 15 at 9:51 AM
Nanalysis Scientific Corp. (NSCIF)Nanalysis Scientific Corp. (NSCIF)
finance.yahoo.com - November 2 at 7:39 AM
Nanalysis Scientific: Top 10 Undervalued Hardware Industry Stocks (NSCI)Nanalysis Scientific: Top 10 Undervalued Hardware Industry Stocks (NSCI)
theglobeandmail.com - October 29 at 5:51 PM
Stories by Chelsea HarveyStories by Chelsea Harvey
scientificamerican.com - October 24 at 1:27 PM
Nanalysis Scientific Corp.s (CVE:NSCI) Share Price Is Matching Sentiment Around Its RevenuesNanalysis Scientific Corp.'s (CVE:NSCI) Share Price Is Matching Sentiment Around Its Revenues
finance.yahoo.com - September 11 at 11:07 AM
Nanalysis Scientific Corp.: Nanalysis Reports Second Quarter 2023 ResultsNanalysis Scientific Corp.: Nanalysis Reports Second Quarter 2023 Results
finanznachrichten.de - August 25 at 6:03 PM
Echelon Wealth Partners Reaffirms Their Buy Rating on Nanalysis Scientific (NSCIF)Echelon Wealth Partners Reaffirms Their Buy Rating on Nanalysis Scientific (NSCIF)
markets.businessinsider.com - August 25 at 8:21 AM
Nanalysis Scientific reports Q2 resultsNanalysis Scientific reports Q2 results
seekingalpha.com - August 24 at 9:24 PM

Media Sentiment Over Time

Company Descriptions

Costa logo

Costa

NASDAQ:ATX
Costa Inc, formerly A. T. Cross Company is a designer and marketer of branded personal accessories, including writing instruments, reading glasses, personal and business accessories and sunglasses. The Company's Cross Optical Group (COG) consists of its wholly owned subsidiary, Cross Optical Group, Inc. and is the legal entity of the Company's two sunglass brands: Costa and Native. The Company's COG designs, manufactures and markets polarized sunglasses under the brand names Costa and Native. The Company's brands offer sunglasses in more than 75 styles and 25 lens options. In September 2013, the Company sold its Cross Accessory Division and the rights to the A.T. Cross name, which was associated with the writing instrument business. Effective February 3, 2014, Essilor International SA acquired Costa Inc.
Biopharmx logo

Biopharmx

NYSEAMERICAN:BPMX
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Hemispherx BioPharma logo

Hemispherx BioPharma

NYSEAMERICAN:HEB
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Nanalysis Scientific logo

Nanalysis Scientific

CVE:NSCI
Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.